QRG Capital Management Inc. Increases Stock Holdings in Takeda Pharmaceutical Co. $TAK

QRG Capital Management Inc. boosted its stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 27.3% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 367,688 shares of the company’s stock after acquiring an additional 78,958 shares during the period. QRG Capital Management Inc.’s holdings in Takeda Pharmaceutical were worth $6,810,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Private Trust Co. NA raised its position in shares of Takeda Pharmaceutical by 84.7% in the fourth quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after buying an additional 783 shares during the last quarter. Parkside Financial Bank & Trust boosted its position in Takeda Pharmaceutical by 192.2% during the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock worth $40,000 after acquiring an additional 1,684 shares during the last quarter. SHP Wealth Management acquired a new position in Takeda Pharmaceutical during the fourth quarter worth about $42,000. Caitong International Asset Management Co. Ltd grew its stake in Takeda Pharmaceutical by 313.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock valued at $48,000 after acquiring an additional 2,328 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its stake in Takeda Pharmaceutical by 56.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after acquiring an additional 1,292 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on TAK shares. Zacks Research cut Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Wall Street Zen lowered Takeda Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Monday. Sanford C. Bernstein upgraded Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a report on Wednesday, April 8th. Finally, Weiss Ratings downgraded Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, June 23rd. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold”.

Takeda Pharmaceutical Trading Down 0.2%

NYSE TAK opened at $16.73 on Monday. The firm has a 50 day simple moving average of $16.09 and a 200-day simple moving average of $16.87. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.60 and a current ratio of 1.09. Takeda Pharmaceutical Co. has a one year low of $12.99 and a one year high of $18.90. The firm has a market cap of $53.26 billion, a price-to-earnings ratio of 42.91 and a beta of -0.07.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. Takeda Pharmaceutical had a return on equity of 11.20% and a net margin of 4.31%.The business had revenue of $6.90 billion for the quarter. Equities research analysts anticipate that Takeda Pharmaceutical Co. will post 0.94 EPS for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.